Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eustratios Bananis

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Rheumatology International|March 13, 2016
Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and AsiaNemanja Damjanov, Waleed Al Shehhi, Feng Huang, et al.
Breast (Edinburgh, Scotland)|August 13, 2021
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2Karen Gelmon, Janice M Walshe, Reshma Mahtani, et al.
Journal of the American Academy of Dermatology|August 29, 2013
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinicsPhilip J Mease, Dafna D Gladman, Kim A Papp, et al.
Rheumatology and Therapy|May 16, 2018
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc AnalysesVibeke Strand, Arthur Kavanaugh, Alan J Kivitz, et al.
Breast Cancer Research : BCR|March 14, 2020
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studiesJohannes Ettl, Seock-Ah Im, Jungsil Ro, et al.
Seminars in Arthritis and Rheumatism|September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis populationAlan J Kivitz, Stanley Cohen, Edward Keystone, et al.
The Journal of Rheumatology|November 17, 2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III StudiesChristina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, et al.
United European Gastroenterology Journal|February 1, 2025
Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis-A Safety AnalysisAnita Afzali, Miguel Regueiro, Andres J Yarur, et al.
Clinical Rheumatology|May 14, 2013
Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE studyKarel Pavelka, Zoltan Szekanecz, Nemanja Damjanov, et al.
Inflammatory Bowel Diseases|March 4, 2025
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical ProgramBruce E Sands, Marla C Dubinsky, Paulo G Kotze, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Rheumatology International|March 13, 2016
Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and AsiaNemanja Damjanov, Waleed Al Shehhi, Feng Huang, et al.
Breast (Edinburgh, Scotland)|August 13, 2021
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2Karen Gelmon, Janice M Walshe, Reshma Mahtani, et al.
Journal of the American Academy of Dermatology|August 29, 2013
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinicsPhilip J Mease, Dafna D Gladman, Kim A Papp, et al.
Rheumatology and Therapy|May 16, 2018
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc AnalysesVibeke Strand, Arthur Kavanaugh, Alan J Kivitz, et al.
Breast Cancer Research : BCR|March 14, 2020
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studiesJohannes Ettl, Seock-Ah Im, Jungsil Ro, et al.
Seminars in Arthritis and Rheumatism|September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis populationAlan J Kivitz, Stanley Cohen, Edward Keystone, et al.
The Journal of Rheumatology|November 17, 2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III StudiesChristina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, et al.
United European Gastroenterology Journal|February 1, 2025
Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis-A Safety AnalysisAnita Afzali, Miguel Regueiro, Andres J Yarur, et al.
Clinical Rheumatology|May 14, 2013
Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE studyKarel Pavelka, Zoltan Szekanecz, Nemanja Damjanov, et al.
Inflammatory Bowel Diseases|March 4, 2025
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical ProgramBruce E Sands, Marla C Dubinsky, Paulo G Kotze, et al.
Pageof 5